CIDEC: A Protein Involved in Inflammation and Drug Targets (G63924)

Target Name: CIDEC

NCBI ID: G63924

CIDEC

CIDEC: A Protein Involved in Inflammation and Drug Targets

CIDEC (CIDEC Variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the superfamily of cysteine-rich proteins (SRP), which are a group of transmembrane proteins that contain a characteristic cysteine-rich region.

The cysteine-rich region of SRP proteins is known for its ability to interact with various molecules, including small molecules, peptides, and proteins. This interaction between the cysteine-rich region and other molecules is important for the function of these proteins.

One of the functions of CIDEC is its role in the regulation of inflammation. CIDEC is a key mediator of the inflammatory response, and it has been shown to play a role in the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

CIDEC is also a potential drug target for several diseases. Its cysteine-rich region makes it a promising target for small molecules that can modulate its activity. Several studies have shown that inhibitors of CIDEC can suppress the growth and metastasis of cancer cells, and may also be effective in treating neurodegenerative diseases.

Another potential application of CIDEC is its use as a biomarker. The cysteine-rich region of CIDEC makes it a potential target for antibodies that can be used to diagnose and monitor the activity of the protein. This could be useful in the development of new diagnostic tests for diseases where the cysteine-rich region is expressed, such as cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, CIDEC (CIDEC Variant 1) is a protein that is expressed in various tissues of the body that is involved in the regulation of inflammation and may be a potential drug target for several diseases. Further research is needed to fully understand its function and potential applications in the development of new treatments.

Protein Name: Cell Death Inducing DFFA Like Effector C

Functions: Lipid transferase specifically expressed in white adipose tissue, which promotes unilocular lipid droplet formation by mediating lipid droplet fusion (PubMed:18334488, PubMed:19843876, PubMed:20049731, PubMed:23399566, PubMed:30361435). Lipid droplet fusion promotes their enlargement, restricting lipolysis and favoring lipid storage (PubMed:18334488, PubMed:19843876, PubMed:20049731, PubMed:23399566). Localizes on the lipid droplet surface, at focal contact sites between lipid droplets, and mediates atypical lipid droplet fusion by undergoing liquid-liquid phase separation (LLPS) and promoting directional net neutral lipid transfer from the smaller to larger lipid droplets (PubMed:18334488, PubMed:19843876, PubMed:20049731, PubMed:23399566). The transfer direction may be driven by the internal pressure difference between the contacting lipid droplet pair (PubMed:18334488, PubMed:19843876, PubMed:20049731, PubMed:23399566). Its role in neutral lipid transfer and lipid droplet enlargement is activated by the interaction with PLIN1 (PubMed:23399566). May also act as a CEBPB coactivator in the white adipose tissue to control the expression of a subset of CEBPB downstream target genes, including SOCS1, SOCS3, TGFB1, TGFBR1, ID2 and XDH (By similarity). When overexpressed in preadipocytes, induces apoptosis or increases cell susceptibility to apoptosis induced by serum deprivation or TGFB treatment (PubMed:12429024)

The "CIDEC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CIDEC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets